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The herpes simplex virus type 1 (HSV-1) mutant in1814 encodes an altered form of the virion protein VP16 that is unable
to transactivate immediate-early (IE) transcription. As a consequence of the mutation, in1814 initiates productive replication
inefficiently after infection of tissue culture cells. Previous studies showed that this defect could be overcome by the
inclusion in the culture medium of hexamethylene bisacetamide (HMBA), a compound that promotes the differentiation of
murine erythroleukemia cells (MELCs). The effects of additional agents known to induce differentiation of MELCs were
investigated. N9-Methylnicotinamide, at concentrations optimal for the induction of MELCs, complemented the replication of
in1814 and stimulated IE gene expression. Suberoyl bishydroxamic acid and suberoylanilide hydroxamic acid, which induce
differentiation of MELCs at micromolar concentrations, did not complement in1814 but specifically blocked the action of
HMBA. The histone deacetylase inhibitor trichostatin A, which also induces differentiation of MELCs, antagonized the effect
of HMBA in a manner similar to that of suberoyl bishydroxamic acid and suberoylanilide hydroxamic acid. The results
demonstrate that the requirement for VP16 activity is dependent on the metabolic state of the host cell and that the pathways
leading to complementation of in1814 and differentiation of MELCs are overlapping but not identical. © 1998 Academic Press
INTRODUCTION
The genome of herpes simplex virus type 1 (HSV-1) is
expressed in a coordinated manner during lytic infection
of mammalian cells (Honess and Roizman, 1974). In the
absence of de novo protein synthesis, only the genes
encoding the five immediate-early (IE) proteins and the
large subunit of ribonucleotide reductase are tran-
scribed. The IE proteins ICP4 (Vmw175) and ICP0
(Vmw110) are important activators of gene expression,
and once they have been produced in adequate quanti-
ties, the viral early and late genes are transcribed and
replication ensues (Everett, 1987). The IE promoters are
activated by the virion protein VP16 (Vmw65 or a-TIF),
which interacts with cellular proteins Oct-1 and HCF to
form an activating complex at the IE-specific sequence
TAATGARAT (R is a purine nucleotide) (O’Hare, 1993). The
HSV-1 mutant in1814 has a 12-bp insertion in the VP16
coding sequences; as a consequence of the mutation,
in1814 is unable to activate IE transcription through the
normal pathway involving VP16 (Ace et al., 1989).
When tissue culture cells are infected with in1814 at an
m.o.i. of ,1 virus particle per cell, only a small proportion
(0.1–1.0%) of cells undergo lytic infection and the majority
of virus–cell interactions result in a nonproductive infec-
tion in which the viral genome is maintained in a quies-
cent state (Ace et al., 1989; Harris and Preston, 1991;
Jamieson et al., 1995; Preston and Nicholl, 1997). The
retained viral genome is converted to a repressed form
and can be induced to resume replication if the HSV-1 IE
protein ICP0 is provided (Harris et al., 1989; Harris and
Preston, 1991; Samaniego et al., 1998). The balance be-
tween the lytic and quiescent outcomes of infection can
be altered dramatically by the addition of the agents
hexamethylene bisacetamide (HMBA) or dimethylsulfox-
ide (DMSO) to the culture medium shortly after infection
of cells with in1814. These compounds stimulate IE gene
expression and thereby enable in1814 to initiate produc-
tive infection essentially as efficiently as wild-type HSV-1
(McFarlane et al., 1992). The cellular pathways by which
HMBA and DMSO mediate their effects on in1814 are
currently unknown.
The concentrations of HMBA and DMSO that give
maximum complementation of in1814 are 5 and 200 mM,
respectively. When these compounds, at the same con-
centrations, are added to murine erythroleukemia cells
(MELCs) and other transformed cell lines, differentiation
to a less transformed phenotype occurs (Reuben et al.,
1980). The mechanism by which the agents promote this
major change in cell physiology is not well understood at
present, but arrest of the cell cycle in G1 phase appears
to be important (Kiyokawa et al., 1993). Nicotinamide and
the derivative N9-methylnicotinamide (N9MeN) also in-
duce differentiation, with N9MeN as effective as HMBA
(Tereda et al., 1979). The potential for the use of HMBA
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as an antitumour agent, based on its ability to reverse
the transformed phenotype, has been investigated in
clinical trials, but the relatively high concentration
needed (5 mM), a short metabolic half-life of the com-
pound, and the observation of side effects were severe
disadvantages (Marks et al., 1994). To investigate further
the mode of action of HMBA and to improve therapy,
“second-generation” inducers of MELC differentiation
have been synthesized and studied. Two of these, sub-
eroyl bishydroxamic acid (SBHA) and suberoylanilide
hydroxamic acid (SAHA), promote differentiation of
MELCs at optimal concentrations of 30 and 3 mM, re-
spectively, and they also arrest cells at the G1/S bound-
ary (Breslow et al., 1991; Stowell et al., 1995; Richon et al.,
1996).
Trichostatin A (TSA) promotes differentiation of MELCs
at submicromolar concentrations and thus is even more
potent than SAHA in this respect (Yoshida et al., 1987).
This compound has received most attention for its activ-
ity as a potent and apparently specific inhibitor of histone
deacetylase both in vitro and in intact cells (Yoshida et
al., 1990), and this property of TSA has been used to
investigate the importance of histone acetylation in gene
regulation. Thus, promoters cloned into adenovirus or
adeno-associated virus genomes were activated from
silent states by the addition of TSA to infected cell cul-
tures (Chen et al., 1997; Dion et al., 1997), suggesting a
role for histone acetylation in reversing the repression of
promoters by cellular factors.
The correlation between the efficacy of HMBA and
DMSO in complementing in1814 and inducing MELC
differentiation suggested that the two processes might
involve common pathways and thus provide important
links between cell metabolic state and the outcome of
infection with HSV-1. There is evidence that IE gene
expression varies during the cell cycle and thus that
arrest of cells at the appropriate stage may overcome the
requirement for VP16. In transfection assays, HSV-1 IE
promoters were more active in cells at the G1 stage
(Ralph et al., 1994), and IE RNA accumulation after infec-
tion with in1814 was also greatest in cells arrested in the
G1 stage (Daksis and Preston, 1992). In addition, HMBA
and DMSO are known to enhance reactivation of HSV-1
from latency after explantation of ganglia from infected
mice (Whitby et al., 1987; Bernstein and Kappes, 1988;
Leib et al., 1989); thus, information on the mode of action
of these chemicals may be relevant to reactivation, a
process that is initiated without functional VP16. We
investigated the effects of nicotinamides, SBHA, SAHA,
and TSA on the replication of in1814 and found that the
correlation with differentiation of MELC holds only par-
tially. Surprisingly, TSA and the second-generation com-
pounds have effects that are antagonistic to those of
HMBA in terms of complementation of in1814.
RESULTS
Effects of nicotinamides on the titre of in1814
Mutant in1814 was titrated on human foetal lung (HFL)
cells, and nicotinamide itself or derivatives (Fig. 1) were
added from the time of infection until 6 h p.i. After this
period, the monolayers were washed and overlaid with
medium containing 5% human serum. At 48 h p.i.,
plaques were counted, and the results are presented in
Table 1. The addition of 5 mM N9MeN was almost as
effective as 5 mM HMBA in complementing in1814, and
the derivative 6-methylnicotinamide also stimulated
plaque formation. Nicotinamide was most effective at 20
mM. The failure of 1-methylnicotinamide and 6-methylni-
cotinic acid to affect the titre of in1814 demonstrates that
the observed activities of N9MeN and 6-methylnicoti-
namide were not nonspecific responses to the presence
of niacin derivatives in the culture medium. The activities
FIG. 1. Structures of chemicals used in the study. The 1, 6, and N9
positions of nicotinamide are shown. In 6-methylnicotinic acid, the
OCONH2 group is replaced by OCOOH.
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of the agents tested and the optimum concentrations
matched closely the potency of the chemicals in promot-
ing MELC differentiation; the percentages of MELC-ex-
pressing hemoglobin after treatment were reported to be
as follows: 5 mM HMBA, .95%; 5 mM N9MeN, 80%; 10
mM N9MeN, .95%; 20 mM nicotinamide, 30%; and
1-methylnicotinamide and 6-methylnicotinic acid, ,0.5%
(Tereda et al., 1979). To our knowledge, the effect of
6-methylnicotinamide on MELC differentiation has not
been reported. Neither HMBA nor the active nicoti-
namides had any effect on the titre of in1814 if added and
removed before infection (McFarlane et al., 1992; C. M.
Preston, unpublished results).
DNA-damaging agents complement in1814
Nicotinamide inhibits poly(ADP-ribosyl)ation, a pro-
cess that is crucial for the proper repair of DNA damage
(Tereda et al., 1979; Durkacz et al., 1980). To investigate
a possible link among DNA damage, poly(ADP-ribosyl)a-
tion, and complementation of in1853, HFL cell monolay-
ers were exposed to varying doses of ultraviolet irradia-
tion (with UV-C; wavelength, 254 nm), either before or
after infection with in1853, but these treatments in-
creased the titre by only 10-fold (results not shown). The
effects of the alkylating agent dimethylsulfate (DMS),
which leads to the formation of 3-methyladenine and
other methylated bases in DNA and subsequent base
excision repair (Sancer and Sancer, 1988), and campto-
thecin, an inhibitor of topoisomerase I that causes sin-
gle-strand breaks in DNA due to a failure to reseal the
nicks made by the enzyme, were also tested (Table 2).
DMS was cytotoxic and could not be used at concentra-
tions of .0.2 mM or for longer than 30 min, but pretreat-
ment of cells with this chemical at the maximum tolera-
ble doses rendered cells permissive to in1853. Campto-
thecin was less toxic than DMS, and pretreatment of
cells with this compound at 30 mM also strongly com-
plemented in1853. Camptothecin was 20-fold less effec-
tive if added 5 h p.i. Therefore, induction of DNA damage
by pretreatment of cells with camptothecin or DMS by-
passed the requirement of HSV-1 for functional VP16.
Complementation of in1814 correlates with increased
IE promoter activity
Previous studies demonstrated that the accumulation
of IE mRNAs, specified by in1814 in the presence of
cycloheximide, was increased ;3-fold by the addition of
HMBA p.i. (McFarlane et al., 1992). This conclusion is
complicated by the recent discovery that cycloheximide
itself activates IE gene expression in the absence of
functional VP16 (Preston et al., 1998); therefore, an ap-
proach more specific to the events that occur shortly p.i.
with in1814 was taken. Mutant in1383 has three muta-
tions: the insertion in VP16, deletion of the crucial RING
domain of ICP0, and the tsK mutation in ICP4, which
inactivates the protein at temperatures of .38°C. In1383
contains, in addition, an insert of lacZ controlled by the
ICP0 promoter. Infection with this mutant and subse-
quent assay of b-galactosidase production gives a mea-
sure of expression from the ICP0 promoter without the
need to use inhibitors to prevent the production of IE
proteins (which would otherwise confuse the interpreta-
tion due to their effects on the cloned promoter). Mutant
in1389 is identical to in1383 except that it has only 154 bp
of the ICP0 promoter controlling lacZ. This portion lacks
TABLE 2






1 None 8.5 3 105
5 mM HMBA 8.1 3 108
0.05 mM DMS 30 6.5 3 106
0.10 mM DMS 30 1.4 3 107
0.15 mM DMS 30 4.9 3 107
0.20 mM DMS 30 1.5 3 108
2 None 7.0 3 105
5 mM HMBA 2.4 3 108
0.20 mM DMS 10 7.0 3 106
0.20 mM DMS 20 2.4 3 107
0.20 mM DMS 30 9.0 3 107
3 None 8.3 3 105
5 mM HMBA 8.7 3 108
1 mM Camptothecin 60 5.3 3 107
3 mM Camptothecin 60 9.9 3 107
10 mM Camptothecin 60 3.4 3 108
30 mM Camptothecin 60 4.0 3 108
10 mM Camptothecin 300 (post) 2.0 3 107
a DMS and camptothecin were added for various times before infec-
tion, except where indicated as p.i. (post).
TABLE 1




1 None 7.3 3 105
5 mM HMBA 5.9 3 108
5 mM N9-Methylnicotinamide 3.0 3 108
10 mM N9-Methylnicotinamide 4.1 3 108
15 mM N9-Methylnicotinamide 3.1 3 108
5 mM 6-Methylnicotinamide 5.5 3 107
10 mM 6-Methylnicotinamide 9.5 3 107
15 mM 6-Methylnicotinamide 7.6 3 107
10 mM 1-Methylnicotinamide 5.9 3 105
10 mM 6-Methylnicotinic acid 8.4 3 105
2 None 3.6 3 105
5 mM HMBA 5.7 3 108
10 mM Nicotinamide 2.3 3 107
15 mM Nicotinamide 5.2 3 107
20 mM Nicotinamide 2.2 3 108
25 mM Nicotinamide 9.5 3 107
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sequences responsive to VP16 but was reported by
O’Rourke and O’Hare (1993) to contain all the elements
necessary for full basal expression from the ICP0. The
effects of HMBA, N9MeN, or pretreatment with campto-
thecin on b-galactosidase production in cells infected
with in1383 or in1389 were examined (Table 3). The
addition of HMBA gave a 30-fold increase in the accu-
mulation of enzyme from in1383, and N9MeN also gave a
substantial (15-fold) stimulation. Pretreatment with camp-
tothecin was less effective but still resulted in a 2-fold
rise in enzyme levels. When in1389 was analysed, the
level of enzyme accumulation was much lower than that
observed with the full ICP0 promoter, but the agents all
increased b-galactosidase accumulation, although the
degree of stimulation was less than that for in1383. To
control for effects of the chemicals on the overall rate of
protein synthesis, cultures maintained in parallel were
radiolabeled with [3H]leucine at 1–6 h p.i., and the incor-
poration into protein was measured. The values, com-
pared with untreated infected cells, were 5 mM HMBA,
95%; 5 mM N9MeN, 71%; and camptothecin pretreatment,
66%, suggesting that major changes in the rate of protein
synthesis did not occur. The results show that the effects
of HMBA, N9MeN and camptothecin were reflected in the
activity of the ICP0 promoter and that a response was
obtained when only nucleotides 2106 to 148 of the
promoter were present.
Effects of SBHA and SAHA
Breslow and colleagues showed that SBHA and SAHA
promote differentiation of MELCs and that they act
additively with suboptimal concentrations of HMBA
(Breslow et al., 1991; Richon et al., 1996). The effects of
these compounds, and their interactions with HMBA,
were tested on the efficiency of plaque formation by
in1814 in HFL cells (Table 4). Unexpectedly, the addition
of SBHA or SAHA alone did not increase the titre of
in1814 but resulted in a small decrease. When added in
combination with 1 or 5 mM HMBA, SBHA and SAHA
dramatically blocked the stimulations normally observed
even though they were present at molarities much lower
than those of HMBA. The new compounds also blocked
the stimulation of in1814 replication by DMSO, N9MeN,
and camptothecin (Table 4). The activity of SAHA was
unchanged over a concentration range of 1–10 mM (re-
sults not shown). To investigate the specificity of the
effect, SBHA and SAHA were added during titration of
1814R (essentially wild-type HSV-1) (Table 5). In1814 was
also titrated in the presence of UV-irradiated tsK (UV-tsK),
which provides VP16 to complement the replication de-
fect of the mutant (Ace et al., 1989). The presence of
SBHA or SAHA at a range of concentrations had no
detectable effect in these situations, demonstrating that
the chemicals did not affect plaque formation when IE
gene expression was activated by VP16 and ruling out
nonspecific inhibition of HSV-1 replication.
To determine whether SBHA and SAHA affect IE gene
expression, HFL cell monolayers were infected with
in1383, with or without UV-tsK, and combinations of
HMBA, SBHA, and SAHA were added. At 6 h p.i., extracts
were made and b-galactosidase assays were performed
(Table 6). SBHA and SAHA prevented the activation by
HMBA but not by VP16; thus, the responses observed in
TABLE 4




1 None 4.3 3 105
5 mM HMBA 4.3 3 108
30 mM SBHA 9.0 3 104
3 mM SAHA 4.5 3 104
5 mM HMBA 1 30 mM SBHA 3.0 3 105
5 mM HMBA 1 3 mM SAHA 5.5 3 105
1 mM HMBA 8.5 3 106
1 mM HMBA 1 30 mM SBHA 2.9 3 105
5 mM N9MeN 2.0 3 108
5 mM N9MeN 1 30 mM SBHA 3.0 3 105
5 mM N9MeN 1 3 mM SAHA 1.0 3 105
2 None 6.5 3 105
5 mM HMBA 8.0 3 105
200 mM DMSO 3.3 3 108
200 mM DMSO 1 30 mM SBHA 4.1 3 105
200 mM DMSO 1 3 mM SAHA 2.3 3 105
3 None 1.9 3 105
5 mM HMBA 4.5 3 108
30 mM Camptothecin 2.0 3 108
30 mM Camptothecin 1 30 mM SBHA 2.3 3 105
30 mM Camptothecin 1 3 mM SAHA 1.6 3 105
a HMBA and DMSO were added at 1–6 h p.i., SBHA and SAHA were
added at 0–6 h p.i., and camptothecin was present for 1 h before
infection.
TABLE 3
Effects of HMBA, N9MeN, and Camptothecin












a HFL cell monolayers were infected with 0.05 pfu of in1383 or in1389
per cell and incubated at 38.5°C for 6 h. Then, 5 mM HMBA was added
at 1–6 h p.i., 5 mM N9MeN was added at 0–6 p.i., and 30 mM campto-
thecin was added for 1 h before infection.
b The mean values of determinations from duplicate cultures are
shown. Values did not vary by .15% from the mean.
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plaque assays correlated with the activity of the ICP0 IE
promoter. Radiolabeling of cells with [3H]leucine demon-
strated that SBHA and SAHA did not detectably affect the
rate of protein synthesis during the period 1–6 h p.i.
(results not shown).
Effects of SBHA and SAHA in MELCs
It was clearly important to determine whether the ef-
fects of SBHA and SAHA on in1814 were also observed
in MELCs, in which the compounds induce differentia-
tion. Because MELCs are suspension cells, it was not
possible to perform plaque assays and thus the progress
of in1814 into the lytic phase was determined by the use
of a new mutant, in1834. This virus was derived from
in1814 by insertion of lacZ, controlled by the UL48 gene
promoter, into the nonessential UL43 gene coding se-
quences. Activity of the UL48 promoter is dependent on
the production of IE proteins; thus, histochemical stain-
ing for b-galactosidase provides a measure of the num-
ber of infected cells that have passed to the lytic stage.
Inclusion of acycloguanosine in the culture medium en-
sured that replication and spread of virus did not occur.
MELCs were infected with in1834 and treated with
HMBA, SBHA, and SAHA individually or in combination,
and histochemical assays were carried out at 6 h p.i.
Uninfected cells were processed in parallel, maintained
for 5 days, and stained with dianisidine to measure
conversion to the erythroid phenotype. The results (Table
7) show that SBHA and SAHA failed to complement
in1834 and antagonised the effects of 1 and 5 mM
HMBA, as found in HFL cells. The compounds behaved
essentially as expected in terms of induction of differen-
tiation, with significant activity of SBHA at 30 mM and of
SAHA at 4 mM (the optimum concentration in our hands
and slightly higher than the reported value of 3 mM;
Richon et al., 1996), respectively. SBHA showed additivity
with 1 mM HMBA, as reported by Breslow et al. (1991).
Although SBHA and SAHA promoted differentiation of
only 50% of cells in the experiments reported in Table 7,
on other occasions these compounds gave 70–80% of
cells positive for hemoglobin. As described previously
(Richon et al., 1996), the optimum concentration for SAHA
was very sharp, so small differences in experimental
procedures and other variables gave relatively large
changes in the degree of differentiation. From the results
in Tables 4–7, therefore, it was possible to dissociate the
effects of SBHA and SAHA on IE gene expression from
their activities in promoting differentiation of MELCs.
TSA inhibits the action of HMBA
TSA is an inducer of MELC differentiation, effective at
submicromolar concentrations, and a potent and specific
inhibitor of histone deacetylases (Yoshida et al., 1987,
1990). The effects of TSA on plaque formation by in1814
and 1814R, with and without HMBA, were investigated
TABLE 5




1814R None 1.0 3 109
1814R 30 mM SBHA 9.8 3 108
1814R 3 mM SAHA 9.6 3 108
in1814 None 8.0 3 105
in1814 1 UV-tsK None 6.2 3 108
in1814 1 UV-tsK 30 mM SBHA 8.0 3 108
in1814 1 UV-tsK 3 mM SAHA 6.2 3 108
TABLE 6





in1383 1 UV-tsK None 52,000
in1383 1 UV-tsK 30 mM SBHA 46,600
in1383 1 UV-tsK 3 mM SAHA 52,400
in1383 5 mM HMBA 24,400
in1383 5 mM HMBA 1 30 mM SBHA 1,500
in1383 5 mM HMBA 1 3 mM SAHA 1,660
in1383 30 mM SBHA 58
in1383 3 mM SAHA 76
Note. The experimental protocol was as described in the legend to
Table 3.
TABLE 7






None 1.9 2 2.0 3 106
5 mM HMBA 17.8 92 1.3 3 106
1 mM HMBA 9.1 28 2.1 3 106
30 mM SBHA 0.3 49 4.4 3 105
4 mM SAHA 0.5 52 1.9 3 105
5 mM HMBA
1 30 mM SBHA
4.2 93 2.5 3 105
1 mM HMBA
1 30 mM SBHA
1.0 47 6.9 3 105
5 mM HMBA
1 4 mM SAHA
3.2 NDd ND
Note. MELC were mock infected or infected with 1 pfu of in 1834 per
cell plus 5 mg/ml acycloguanosine, and various agents were added
after a 1 h adsorption period.
a Infected cells were stained for b-galactosidase expression at 6 h
p.i.
b Mock infected cells were stained with dianisidine after 5 days.
c Cell numbers of mock infected cells were determined after 5 days.
d Not determined.
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(Table 8A). TSA, even at the highest concentration tested
(1 mM) did not increase the titre of in1814, but like SAHA,
the compound inhibited the effect of HMBA. The titre of
1814R was not affected by the presence of 1 mM TSA.
When expression from the ICP0 promoter of in1383 was
examined (Table 8B), TSA inhibited the action of HMBA
but not UV-tsK in a manner analogous to that of SAHA
(Table 6). The addition of TSA alone did not stimulate
expression from the ICP0 promoter within the in1383
genome (Table 8B). Therefore, TSA, like SAHA and
SBHA, blocked the activation of IE gene expression in an
apparently specific manner.
DISCUSSION
Three main conclusions follow from the experiments
described here. First, the results emphasize that the
absence of VP16 function can be overcome by a diversity
of treatments to cells, suggesting that in the appropriate
intracellular environment in vivo, the protein may not be
required for efficient initiation of the lytic cycle. Second,
the correlation between complementation of in1814 and
differentiation of MELC does not hold absolutely; further-
more, SBHA and SAHA can exert effects that either
enhance or nullify the activity of HMBA depending on the
assay used. Third, the histone deacetylase inhibitor TSA,
which in some systems activates the expression of oth-
erwise silent genes, has properties similar to those of
SBHA and SAHA in terms of effects on HSV-1.
Complementation of in1814 by nicotinamides shows
that relatively simple naturally occurring compounds can
influence the permissiveness of cells to HSV-1 infection
in the absence of functional VP16. The mode of action of
these compounds, like that of HMBA and DMSO, is not
known at present, but it is noteworthy that specific fea-
tures of the nicotinamide ring are crucial for their activ-
ities. Thus, N9MeN and 6-methylnicotinamide can be
assimilated into derivatives of NAD1 that may be of low
activity in some of the many roles [cellular oxidation/
reduction reactions, substrate for poly(ADP-ribose) syn-
thesis] of the cofactor. By contrast, 1-methylnicotinamide
cannot be incorporated into an NAD1 adduct, and the
dinucleotide formed with 6-methylnicotinic acid may not
be recognised by enzymes that use NAD1. The optimum
concentrations of N9MeN and, especially, nicotinamide
itself are much higher than those under physiological
conditions [the intracellular concentration of NAD1 is ,1
mM (Tereda et al., 1979)]; thus, an additional possibility is
that the agents act primarily at the cell membrane as has
been postulated for polar–planar compounds such as
HMBA (Marks et al., 1994). There is a previous example
of activation of gene expression by N9MeN: the com-
pound, at a concentration of 10 mM, stimulates the ac-
tivity of the rat growth hormone gene promoter (Sanchez-
Pachecho and Aranda, 1992).
Induction of cellular DNA damage is known to activate
signal transduction pathways that converge on transcrip-
tion factors such as AP-1 and ATF (Devary et al., 1991;
Stein et al., 1992), although the effects resulting from UV
irradiation of cells are understood best. The stimulation
of in1814 replication by camptothecin defines a mode of
action different than that of HMBA because the topo-
isomerase I inhibitor acts before infection, altering cells
such that IE gene expression is increased, but it does not
exert a direct effect on HSV-1 IE promoters. This obser-
vation is important because it establishes that preexist-
ing variations in cellular metabolic state can profoundly
affect the outcome of infection with in1814, whereas
HMBA and the other compounds described here are only
effective if present during virus infection and thus may
themselves have direct effects on IE transcription. It
should be noted, however, that camptothecin pretreat-
ment may not act solely by increasing IE gene expres-
sion because a large stimulation of plaque formation
was observed while b-galactosidase production from
in1383 was increased only by 2-fold (Tables 2 and 3). In
the experiments described in Tables 4 and 6, a combi-
nation of HMBA and SBHA had no effect on the basal
titre of in1814 but still gave a 6-fold increase in enzyme
levels expressed by in1383. The fact that DNA-damaging
agents and HMBA induce the expression of cellular
proto-oncogenes c-fos and c-jun may provide a link to
reactivation of HSV-1 from latency because it has been
shown that these genes are induced during explantation
of ganglia and may play a role in the reactivation process
TABLE 8
Effects of TSA
Virus Agents added Titre (pfu/ml)
A. Effects on the titre of in1814
in1814 None 1.4 3 105
in1814 1.0 mM TSA 1.8 3 105
in1814 5 mM HMBA 3.8 3 108
in1814 5 mM HMBA 1 0.1 mM TSA 3.1 3 107
in1814 5 mM HMBA 1 0.3 mM TSA 2.4 3 106
in1814 5 mM HMBA 1 1.0 mM TSA 8.0 3 105
1814R None 3.0 3 108




B. Effects on ICP0 promoter activitya
in1383 None 650
in1383 1 UV-tsK None 35,200
in1383 1 UV-tsK 1.0 mM TSA 30,600
in1383 5 mM HMBA 14,300
in1383 5 mM HMBA 1 1.0 mM TSA 2,190
in1383 1.0 mM TSA 390
a The experimental protocol was as described in the legend to
Table 3.
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(Ramsay et al., 1986; Valyi-Nagi et al., 1991; Tal-Singer et
al., 1997).
The finding that SBHA and SAHA antagonise the effect
of HMBA, and other agents that complement in1814, was
unexpected and demonstrates that the pathways leading
to differentiation of MELC only partially overlap those
that act on in1814. Because SBHA and SAHA do not
affect the stimulation of IE transcription by VP16, the
compounds presumably interfere specifically with one or
more of the processes activated by HMBA. The fact that
the new agents act at concentrations 2 or 3 orders of
magnitude lower than that of HMBA shows that they are
very potent inhibitors of certain cellular reactions and
that the elucidation of the targets for SBHA and SAHA
should reveal new aspects of intracellular signaling
pathways that influence HSV-1 IE gene expression.
The inhibitory effect of TSA on HMBA-mediated gene
expression contrasts with its effects on other viruses.
When cells infected with an E1A-deficient adenovirus
recombinant containing the firefly luciferase gene con-
trolled by the human cytomegalovirus (HCMV) major IE
promoter were treated with 1 mM TSA, a 100-fold in-
crease in luciferase expression was oserved (Dion et al.,
1997). Similarly, the addition of TSA to cells transduced
by an adeno-associated virus recombinant containing
the lacZ gene controlled by the HCMV IE promoter reac-
tivated expression from the silenced transgene (Chen et
al., 1997). In cells infected with in1383 or an analogous
mutant, in1382, in which the HCMV IE promoter con-
trolled lacZ (Preston et al., 1998), the presence of TSA
resulted in a reduction in b-galactosidase expression
(Table 8 and our unpublished results). These observa-
tions suggest that histone acetylation does not stimulate
expression from the ICP0 or HCMV IE promoters within
the HSV-1 genome, at least during the early stages of
infection. In a recent publication, Richon et al. (1998)
showed that SBHA and SAHA, which are structurally
related to TSA (Fig. 1), are also inhibitors of histone
deacetylase. Inhibition of histone deacetylase may there-
fore be important for blocking the action of HMBA on
HSV-1 IE gene expression.
MATERIALS AND METHODS
Chemicals
SBHA (Aldrich Chemical Co.) and SAHA (a generous
gift from the late J. Stowell) were dissolved at 0.1 M in
DMSO. All other chemicals were obtained from Sigma
Chemical Co. The chemical structures of some of the
agents used are shown in Figure 1.
Cells and viruses
HFL fibroblasts were propagated as described previ-
ously (Harris and Preston, 1991). BHK-21 (C13) cells were
used for routine propagation and titration of HSV-1
stocks. MELC (clone 707) were obtained from the Euro-
pean Collection of Animal Cell Cultures and grown as
suspension cultures in Dulbecco’s modified Eagle’s me-
dium supplemented with 20% (v/v) foetal calf serum.
Staining with diaminobenzidine for hemoglobin was car-
ried out as described by Minegishi et al. (1994). The
HSV-1 mutant in1814 and the rescuant 1814R have been
described previously (Ace et al., 1989). Mutant in1853 is
in1814 with an insertion of the Escherichia coli lacZ
coding sequences at the thymidine kinase (TK) locus
(Ecob-Prince et al., 1994). The derivative in1834 was
constructed by cotransfection of in1814 DNA with plas-
mid pCP12110. Plasmid pCP12110 contained the lacZ
gene plus Simian virus 40 termination sequences, de-
rived from pCH110 (Pharmacia), controlled by the pro-
moter of UL48 from a TaqI site to an EcoRV site (2239 to
1156 with respect to the mRNA start site). The promoter–
lacZ–terminator cassette was cloned between the BstXI
and BamHI sites within the UL43 coding sequences in
the plasmid p35 (MacLean et al., 1991; kindly provided by
C. MacLean) to yield pCP12110. Virus isolates that ex-
pressed b-galactosidase were selected from the trans-
fected cells and plaque purified, and their genetic struc-
tures confirmed by Southern hybridization. An isolate that
was free from any detectable trace of parental in1814
was designated in1834. Mutant in1383 has been de-
scribed previously (Preston et al., 1998): it has the VP16
mutation of in1814, a deletion of the essential RING
domain of ICP0 (Everett, 1989; Everett et al., 1993), the
temperature-sensitive mutation of tsK that inactivates the
transactivator protein ICP4 at temperatures of .38°, and
an insertion of the ICP0 promoter (from 2808 to 148)
controlling lacZ inserted at the viral TK locus. Mutant
in1389 is identical to in1383 except that the sequences
controlling lacZ consist only of nucleotides 2106 to 148
of the ICP0 promoter. The ICP4 temperature-sensitive
mutant tsK was irradiated with UV light to reduce its titre
by a factor of 5 3 105 to yield UV-tsK, as described by
Notarianni and Preston (1982).
Determination of virus titres
The effects of various agents on the titre of VP16-
deficient HSV-1 were determined by infection either with
in1814 followed by staining with Giemsa’s stain or with
in1853 and subsequent histochemical staining to detect
b-galactosidase expression in plaques. HMBA and
DMSO were added at 1–6 h p.i., whereas other agents
were present at 0–6 h p.i., except where stated in figure
legends. The time of the addition of chemicals (0 or 1 h)
did not significantly affect the results obtained (data not
shown). UV-tsK was added at 1 pfu/cell, based on the
titre before irradiation. At 6 h p.i., the culture medium
was thoroughly removed, and monolayers were overlaid
with Eagle’s medium containing 5% (v/v) pooled human
serum.
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b-Galactosidase assays
Histochemical detection of b-galactosidase in fixed
cells was carried out as described previously (Jamieson
et al., 1995). For direct assay of b-galactosidase, cells
were harvested, washed in phosphate-buffered saline,
and lysed by the addition of a buffer containing 10 mM
Tris–HCl, pH 7.5, 2 mM MgCl2, 10 mM NaCl, and 0.1%
(v/v) Nonidet-P40. Extracts were added to reaction mix-
tures containing 50 mM glycine–NaOH, pH 9.0, 2 mM
MgCl2, 125 mM NaCl, 6.5 mM b-mercaptoethanol, and 1
mg/ml 4-methylumbelliferyl-b-D-galactoside. After incu-
bation at 37°C for the appropriate times, reactions were
terminated by the addition of trichloroacetic acid to a
final concentration of 5% (v/v). Mixtures were stored on
ice for $5 min and centrifuged at 10,000 g for 2 min, and
varying amounts of the supernatant were added to 2 ml
of 133 mM glycine and 83 mM Na2CO3, pH 10.7. Fluo-
rescence was measured in a TKO 100 fluorometer (Bio-
tech Instruments Ltd., Luton, UK). Enzyme activities are
expressed as arbitrary fluorescence units after correc-
tion for protein content of extracts.
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